Teicoplanin-induced leucopenia with immediate resolution after administration of G-CSF.
Teicoplanin is used in a wide range of clinical settings, owing to its wide antiGram positive bacterial activity. Although it is generally well tolerated, adverse reactions such as fever and rash are well recognised. Haematological sequelae have been rarely reported. This case report describes the development of teicoplanin-induced leucopenia in a patient with infective endocarditis. A short course of lenograstim, a recombinant granulocyte colony-stimulating factor (G-CSF) reverted biochemical abnormalities. To the authors' best knowledge, this is the first documented example of implementation of G-CSF in such a clinical setting.
Leeds General Infirmary, Leeds, UK. peysh@doctors.org.uk
Peysh
P
Patel
Jonathan
J
Sandoe
Wazir
W
Baig
D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000368:Aged; D000900:Anti-Bacterial Agents / Q000009:adverse effects*; D004697:Endocarditis, Bacterial / Q000188:drug therapy; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use*; D006801:Humans; D000078224:Lenograstim; D007970:Leukopenia / Q000139:chemically induced* / Q000188:drug therapy*; D008297:Male; D011994:Recombinant Proteins / Q000627:therapeutic use; D017334:Teicoplanin / Q000009:adverse effects*
D000276:Adjuvants, Immunologic; D000900:Anti-Bacterial Agents; D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor; D017334:Teicoplanin; D000078224:Lenograstim